Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 19Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 10Paclitaxel 8Bevacizumab 7Cyclophosphamide 6olaparib 5niraparib 5Fulvestrant 4talazoparib 3Radiotherapy 3Gemcitabine 3Capecitabine 3veliparib 2palbociclib 2eribulin 2dostarlimab 2aldesleukin 2Trastuzumab 2Specimen Handling 2Letrozole 2Drug Therapy 2Doxorubicin 2Cisplatin 2Celecoxib 2Biopsy 2Albumin-Bound Paclitaxel 2tucotuzumab celmoleukin 1trastuzumab duocarmazine 1trastuzumab biosimilar HLX02 1sotigalimab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ovarian Neoplasms × Bortezomib × Clear all
NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Millennium Pharmaceuticals, Inc.

Phase 2 Withdrawn
91 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡